UK Promises Reduced Trial Burden For Biosimilars

MHRA Sets Out Plans For ‘Innovative’ Procedure After EU Transition

 
• By David Wallace
  
Heavy box
The MHRA is planning to reduce the trial burden for biosimilars • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Regulation

More from Policy & Regulation